The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Urinary Tract Cancer-Global Market Insights and Sales Trends 2025
Synopsis
One of the early symptoms of urinary tract cancer is the presence of blood in the urine, haematuria. As cited in WHO report urinary tract cancer was the ninth-most highly occurent cancer types in 2012 and have high reoccurrence rate as well.
The global Urinary Tract Cancer market size is expected to reach US$ 7376.1 million by 2029, growing at a CAGR of 17.2% from 2023 to 2029. The market is mainly driven by the significant applications of Urinary Tract Cancer in various end use industries. The expanding demands from the Hospitals, Clinics, Research Centers and Others, are propelling Urinary Tract Cancer market. Urothelial Carcinoma, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Squamous Cell Carcinoma segment is estimated at % CAGR for the next seven-year period.
The major factors favoring the growth of the urinary tract cancer treatment market are increasing incidence of urinary tract cancer worldwide owing to rising sedentary lifestyle, geriatric population, rising smoking population and rigorous research activities towards developing urinary tract cancer therapeutics. Clinical trial review of the therapeutics to treat urinary tract cancer seems to provide a lucrative growth prospects for this market.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Urinary Tract Cancer, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Urinary Tract Cancer market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Urinary Tract Cancer market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Urinary Tract Cancer sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Urinary Tract Cancer covered in this report include Spectrum Pharmaceuticals, Bristol-Myers Squibb Company, Genzyme Corporation, F. Hoffmann-La Roche, Shionogi, Kyowa Hakko Kirin, Medical Enzymes, IkerChem and Amgen, etc.
The global Urinary Tract Cancer market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Spectrum Pharmaceuticals
Bristol-Myers Squibb Company
Genzyme Corporation
F. Hoffmann-La Roche
Shionogi
Kyowa Hakko Kirin
Medical Enzymes
IkerChem
Amgen
Boehringer Ingelheim GmbH
Astellas Pharma Inc
Eli Lilly and Company
Endo International Plc
Exelixis Inc
GlaxoSmith Plc
Merck KGaA
Novartis AG
Pfizer Inc
Johnson & Johnson
Global Urinary Tract Cancer market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Urinary Tract Cancer market, Segment by Type:
Urothelial Carcinoma
Squamous Cell Carcinoma
Adenocarcinoma
Others
Global Urinary Tract Cancer market, by Application
Hospitals
Clinics
Research Centers
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Urinary Tract Cancer companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
One of the early symptoms of urinary tract cancer is the presence of blood in the urine, haematuria. As cited in WHO report urinary tract cancer was the ninth-most highly occurent cancer types in 2012 and have high reoccurrence rate as well.
The global Urinary Tract Cancer market size is expected to reach US$ 7376.1 million by 2029, growing at a CAGR of 17.2% from 2023 to 2029. The market is mainly driven by the significant applications of Urinary Tract Cancer in various end use industries. The expanding demands from the Hospitals, Clinics, Research Centers and Others, are propelling Urinary Tract Cancer market. Urothelial Carcinoma, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Squamous Cell Carcinoma segment is estimated at % CAGR for the next seven-year period.
The major factors favoring the growth of the urinary tract cancer treatment market are increasing incidence of urinary tract cancer worldwide owing to rising sedentary lifestyle, geriatric population, rising smoking population and rigorous research activities towards developing urinary tract cancer therapeutics. Clinical trial review of the therapeutics to treat urinary tract cancer seems to provide a lucrative growth prospects for this market.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Urinary Tract Cancer, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Urinary Tract Cancer market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Urinary Tract Cancer market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Urinary Tract Cancer sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Urinary Tract Cancer covered in this report include Spectrum Pharmaceuticals, Bristol-Myers Squibb Company, Genzyme Corporation, F. Hoffmann-La Roche, Shionogi, Kyowa Hakko Kirin, Medical Enzymes, IkerChem and Amgen, etc.
The global Urinary Tract Cancer market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Spectrum Pharmaceuticals
Bristol-Myers Squibb Company
Genzyme Corporation
F. Hoffmann-La Roche
Shionogi
Kyowa Hakko Kirin
Medical Enzymes
IkerChem
Amgen
Boehringer Ingelheim GmbH
Astellas Pharma Inc
Eli Lilly and Company
Endo International Plc
Exelixis Inc
GlaxoSmith Plc
Merck KGaA
Novartis AG
Pfizer Inc
Johnson & Johnson
Global Urinary Tract Cancer market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Urinary Tract Cancer market, Segment by Type:
Urothelial Carcinoma
Squamous Cell Carcinoma
Adenocarcinoma
Others
Global Urinary Tract Cancer market, by Application
Hospitals
Clinics
Research Centers
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Urinary Tract Cancer companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Urinary Tract Cancer
1.1 Urinary Tract Cancer Market Overview
1.1.1 Urinary Tract Cancer Product Scope
1.1.2 Urinary Tract Cancer Market Status and Outlook
1.2 Global Urinary Tract Cancer Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Urinary Tract Cancer Market Size by Region (2018-2029)
1.4 Global Urinary Tract Cancer Historic Market Size by Region (2018-2023)
1.5 Global Urinary Tract Cancer Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Urinary Tract Cancer Market Size (2018-2029)
1.6.1 North America Urinary Tract Cancer Market Size (2018-2029)
1.6.2 Europe Urinary Tract Cancer Market Size (2018-2029)
1.6.3 Asia-Pacific Urinary Tract Cancer Market Size (2018-2029)
1.6.4 Latin America Urinary Tract Cancer Market Size (2018-2029)
1.6.5 Middle East & Africa Urinary Tract Cancer Market Size (2018-2029)
2 Urinary Tract Cancer Market by Type
2.1 Introduction
2.1.1 Urothelial Carcinoma
2.1.2 Squamous Cell Carcinoma
2.1.3 Adenocarcinoma
2.1.4 Others
2.2 Global Urinary Tract Cancer Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Urinary Tract Cancer Historic Market Size by Type (2018-2023)
2.2.2 Global Urinary Tract Cancer Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Urinary Tract Cancer Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Urinary Tract Cancer Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Urinary Tract Cancer Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Urinary Tract Cancer Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Urinary Tract Cancer Revenue Breakdown by Type (2018-2029)
3 Urinary Tract Cancer Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Research Centers
3.1.4 Others
3.2 Global Urinary Tract Cancer Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Urinary Tract Cancer Historic Market Size by Application (2018-2023)
3.2.2 Global Urinary Tract Cancer Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Urinary Tract Cancer Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Urinary Tract Cancer Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Urinary Tract Cancer Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Urinary Tract Cancer Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Urinary Tract Cancer Revenue Breakdown by Application (2018-2029)
4 Urinary Tract Cancer Competition Analysis by Players
4.1 Global Urinary Tract Cancer Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Urinary Tract Cancer as of 2022)
4.3 Date of Key Players Enter into Urinary Tract Cancer Market
4.4 Global Top Players Urinary Tract Cancer Headquarters and Area Served
4.5 Key Players Urinary Tract Cancer Product Solution and Service
4.6 Competitive Status
4.6.1 Urinary Tract Cancer Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Spectrum Pharmaceuticals
5.1.1 Spectrum Pharmaceuticals Profile
5.1.2 Spectrum Pharmaceuticals Main Business
5.1.3 Spectrum Pharmaceuticals Urinary Tract Cancer Products, Services and Solutions
5.1.4 Spectrum Pharmaceuticals Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.1.5 Spectrum Pharmaceuticals Recent Developments
5.2 Bristol-Myers Squibb Company
5.2.1 Bristol-Myers Squibb Company Profile
5.2.2 Bristol-Myers Squibb Company Main Business
5.2.3 Bristol-Myers Squibb Company Urinary Tract Cancer Products, Services and Solutions
5.2.4 Bristol-Myers Squibb Company Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.2.5 Bristol-Myers Squibb Company Recent Developments
5.3 Genzyme Corporation
5.3.1 Genzyme Corporation Profile
5.3.2 Genzyme Corporation Main Business
5.3.3 Genzyme Corporation Urinary Tract Cancer Products, Services and Solutions
5.3.4 Genzyme Corporation Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.3.5 F. Hoffmann-La Roche Recent Developments
5.4 F. Hoffmann-La Roche
5.4.1 F. Hoffmann-La Roche Profile
5.4.2 F. Hoffmann-La Roche Main Business
5.4.3 F. Hoffmann-La Roche Urinary Tract Cancer Products, Services and Solutions
5.4.4 F. Hoffmann-La Roche Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.4.5 F. Hoffmann-La Roche Recent Developments
5.5 Shionogi
5.5.1 Shionogi Profile
5.5.2 Shionogi Main Business
5.5.3 Shionogi Urinary Tract Cancer Products, Services and Solutions
5.5.4 Shionogi Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.5.5 Shionogi Recent Developments
5.6 Kyowa Hakko Kirin
5.6.1 Kyowa Hakko Kirin Profile
5.6.2 Kyowa Hakko Kirin Main Business
5.6.3 Kyowa Hakko Kirin Urinary Tract Cancer Products, Services and Solutions
5.6.4 Kyowa Hakko Kirin Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.6.5 Kyowa Hakko Kirin Recent Developments
5.7 Medical Enzymes
5.7.1 Medical Enzymes Profile
5.7.2 Medical Enzymes Main Business
5.7.3 Medical Enzymes Urinary Tract Cancer Products, Services and Solutions
5.7.4 Medical Enzymes Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.7.5 Medical Enzymes Recent Developments
5.8 IkerChem
5.8.1 IkerChem Profile
5.8.2 IkerChem Main Business
5.8.3 IkerChem Urinary Tract Cancer Products, Services and Solutions
5.8.4 IkerChem Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.8.5 IkerChem Recent Developments
5.9 Amgen
5.9.1 Amgen Profile
5.9.2 Amgen Main Business
5.9.3 Amgen Urinary Tract Cancer Products, Services and Solutions
5.9.4 Amgen Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.9.5 Amgen Recent Developments
5.10 Boehringer Ingelheim GmbH
5.10.1 Boehringer Ingelheim GmbH Profile
5.10.2 Boehringer Ingelheim GmbH Main Business
5.10.3 Boehringer Ingelheim GmbH Urinary Tract Cancer Products, Services and Solutions
5.10.4 Boehringer Ingelheim GmbH Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.10.5 Boehringer Ingelheim GmbH Recent Developments
5.11 Astellas Pharma Inc
5.11.1 Astellas Pharma Inc Profile
5.11.2 Astellas Pharma Inc Main Business
5.11.3 Astellas Pharma Inc Urinary Tract Cancer Products, Services and Solutions
5.11.4 Astellas Pharma Inc Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.11.5 Astellas Pharma Inc Recent Developments
5.12 Eli Lilly and Company
5.12.1 Eli Lilly and Company Profile
5.12.2 Eli Lilly and Company Main Business
5.12.3 Eli Lilly and Company Urinary Tract Cancer Products, Services and Solutions
5.12.4 Eli Lilly and Company Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.12.5 Eli Lilly and Company Recent Developments
5.13 Endo International Plc
5.13.1 Endo International Plc Profile
5.13.2 Endo International Plc Main Business
5.13.3 Endo International Plc Urinary Tract Cancer Products, Services and Solutions
5.13.4 Endo International Plc Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.13.5 Endo International Plc Recent Developments
5.14 Exelixis Inc
5.14.1 Exelixis Inc Profile
5.14.2 Exelixis Inc Main Business
5.14.3 Exelixis Inc Urinary Tract Cancer Products, Services and Solutions
5.14.4 Exelixis Inc Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.14.5 Exelixis Inc Recent Developments
5.15 GlaxoSmith Plc
5.15.1 GlaxoSmith Plc Profile
5.15.2 GlaxoSmith Plc Main Business
5.15.3 GlaxoSmith Plc Urinary Tract Cancer Products, Services and Solutions
5.15.4 GlaxoSmith Plc Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.15.5 GlaxoSmith Plc Recent Developments
5.16 Merck KGaA
5.16.1 Merck KGaA Profile
5.16.2 Merck KGaA Main Business
5.16.3 Merck KGaA Urinary Tract Cancer Products, Services and Solutions
5.16.4 Merck KGaA Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.16.5 Merck KGaA Recent Developments
5.17 Novartis AG
5.17.1 Novartis AG Profile
5.17.2 Novartis AG Main Business
5.17.3 Novartis AG Urinary Tract Cancer Products, Services and Solutions
5.17.4 Novartis AG Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.17.5 Novartis AG Recent Developments
5.18 Pfizer Inc
5.18.1 Pfizer Inc Profile
5.18.2 Pfizer Inc Main Business
5.18.3 Pfizer Inc Urinary Tract Cancer Products, Services and Solutions
5.18.4 Pfizer Inc Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.18.5 Pfizer Inc Recent Developments
5.19 Johnson & Johnson
5.19.1 Johnson & Johnson Profile
5.19.2 Johnson & Johnson Main Business
5.19.3 Johnson & Johnson Urinary Tract Cancer Products, Services and Solutions
5.19.4 Johnson & Johnson Urinary Tract Cancer Revenue (US$ Million) & (2018-2023)
5.19.5 Johnson & Johnson Recent Developments
6 North America
6.1 North America Urinary Tract Cancer Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Urinary Tract Cancer Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Urinary Tract Cancer Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Urinary Tract Cancer Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Urinary Tract Cancer Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Urinary Tract Cancer Market Dynamics
11.1 Urinary Tract Cancer Industry Trends
11.2 Urinary Tract Cancer Market Drivers
11.3 Urinary Tract Cancer Market Challenges
11.4 Urinary Tract Cancer Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
